Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT trial: preventive HIPEC plus perioperative FLOT versus FLOT alone in resectable diffuse gastric or gastroesophageal junction adenocarcinoma
2024-517300-10-01Phase 3Authorised
- Sponsor
- Krankenhaus Nordwest
- Start
- Dec 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, folinic acid, oxaliplatin, docetaxel and cisplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Krankenhaus Nordwest. Primary endpoint: Progression-free survival / disease-free survival. Planned start Dec 2020; status: authorised.
02
Drugs
fluorouracilfolinic acidoxaliplatindocetaxelcisplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-517300-10-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517300-10-01.